New Drug Watch: Alzheimer Drug Still Controversial

Cynthia Challener discusses ongoing questions about the rapid approval and continuing concerns regarding the safety and efficacy of Aducanumab, the first drug shown to reduce amyloid plaques for the treatment of Alzheimer’s disease.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: